Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DaVita names new CMO
Dr Nissenson is a former president of the Renal Physicians Association and serves on the RPA board of directors as a special advisor to the current president. Kent
Dr Nissenson is a former president of the Renal Physicians Association and serves on the RPA board of directors as a special advisor to the current president. Kent
The study is a three-arm, randomized trial which will enroll up to 180 patients at cancer centers in North America and Europe. Charles Craddock, professor of haemato-oncology at
The collaboration will leverage microRNAs’s significant potential as highly sensitive and specific biomarkers, to develop a wide range of diagnostic and prognostic tests. This is the company’s first
The mutual goal is to provide the ‘picks and shovels’ for scientists mining the stem cell field for therapeutics in the emerging field of regenerative medicine and pharmaceutical
As announced previously, the OVA1 prospective clinical trial met its primary endpoints, indicating that the test is capable of stratifying women with pelvic masses into high- and low-risk
Acuvue Oasys for astigmatism combines the accelerated stabilization design (ASD) technology of Acuvue Advance brand contact lenses for astigmatism, with senofilcon A, the new generation silicone hydrogel material
Dr Ramachandra succeeds Edward Ogunro who retired on December 31, 2007, and will report directly to Christopher Begley, chairman and CEO. Most recently, Dr Ramachandra served as vice
The co-operative research and development agreement, initiated in March 2006, was extended through September 2009. John Kovach, president and CEO of Lixte, said: “The scientific interaction with the
This new E100 million facility, located in Val de Reuil (North West of France), incorporates the latest technology to produce vaccines that meet the highest standards of quality.
The interim results represent data from the first 80 patients enrolled in the targeted 100-patient clinical trial. Approximately 30 healthy subjects were enrolled to evaluate the efficacy of